Zacks Investment Research
13 Aug 2026, 23:51 UTC · 1w ago
NewsImpactScreener rates every claim in this story for market impact and maps it to the tickers most exposed.
Analysis by Kasper Rasmussen · Founder & analyst
What the story claims
3 claims · each scored for market impact
CAMP4 Therapeutics reported quarterly revenue of $1.78 million, exceeding the Zacks Consensus Estimate by 31.78%. — A significant revenue beat suggests better-than-expected commercial or operational momentum for a small-cap biotech.
+0.40CAMP4 Therapeutics reported a quarterly loss of $0.22 per share, which was slightly better than the estimated loss of $0.24. — The earnings beat is marginal (8.33%) and the company remains loss-making, limiting the positive catalyst.
+0.20CAMP4 Therapeutics shares have declined approximately 26.1% year-to-date, underperforming the S&P 500's 13.2% gain. — Strong negative price momentum indicates low investor confidence despite the recent slight earnings beat.
-0.10Which stocks this story touches
Continue reading
6 related stories
Search tags
The company reported a quarterly loss that was smaller than estimated and revenues that surpassed consensus estimates.
Free · No account
Get a free daily PDF briefing — the last 24 hours of news, with summaries and the market-impact score for each story, delivered an hour before the open.
We’ll watch
Pre-filled from this story — remove any you don’t want. Add more tickers & tags or fine-tune your watchlist anytime — every email has an edit link, no account needed.
Free forever · one email a day, max · unsubscribe in one click.How it works
How the impact breaks down
Where the story's weight lands
Stocks most exposed
Modeled from each name's sensitivity to this story
No stock impact ranking available yet.
Zacks Investment Research
5h ago
